ONC · BeOne Medicines Ltd.

The thesis

BeOne Medicines' Q3 report on 5 November 2026 answered the question the previous note left open: US BRUKINSA sales grew 36% and full-year revenue guidance rose to $6.9–7.0 billion. The case now rests on whether that growth carries into 2027, which the Q4 report and its outlook settle.

Q3 revenue was $1.89 billion, up 34% year over year, against 30% growth in Q2 (8-K exhibit). Benzinga reported a $1.758 billion revenue estimate. The prior guidance range was $6.6–6.8 billion, and Benzinga put the estimate at $6.763 billion.

The shares closed at $387.25 on 5 November 2026, a 52-week high in adjusted daily closes. The narrative is maturing: the BRUKINSA story is well known, and the 5 November 2026 report extended it with a three-month share gain of 7.9%.

Bullish and bearish views on BeOne Medicines Ltd.

The bull case on BeOne Medicines Ltd. (ONC), in brief: US BRUKINSA passed $1 billion in a quarter. The bear case: Guidance points to a softer fourth quarter.

Bull case

• US BRUKINSA passed $1 billion in a quarter. The Q3 10-Q shows US sales of $1,005.1 million, and the 8-K gives growth of 36%.
• Benzinga reported adjusted earnings of $4.59 per ADS against a $1.97 estimate.
• Profit guidance moved up with revenue. On 5 November 2026 BeOne raised 2026 GAAP operating income guidance to $1.2–1.3 billion from $1.0–1.1 billion. Non-GAAP operating income guidance rose to $1.9–2.0 billion from $1.7–1.8 billion.
• Cash generation is strong. Q3 free cash flow was $473.5 million, up 34%, and cash stood at $5.87 billion on 30 September 2026, per the 8-K.
• First-line lymphoma is the next BRUKINSA label. The 5 November 2026 release says the FDA granted Priority Review for the MANGROVE filing in mantle cell lymphoma, with EU and China submissions complete. Interim results get a Plenary Scientific Session at the American Society of Hematology (ASH) 2026 meeting.
• The pipeline moved toward filings. Tacabrutideg, a BTK protein degrader, met its primary response-rate endpoint in the pivotal Phase 2 portion of CaDAnCe-101 in relapsed chronic lymphocytic leukemia (CLL), per the 5 November 2026 release. BeOne plans a potential submission in mid-2027.
• Analyst targets sit above the close. RBC's target is $459 (8 October 2026), TD Cowen's $454 (6 August 2026), JPMorgan's $445 (1 October 2026), Truist's $420 (7 October 2026) and Barclays' $415 (10 September 2026). All predate the Q3 report.

Bear case

• Guidance points to a softer fourth quarter. On the 5 November 2026 call, Guggenheim's Michael Schmidt asked why the new range implied flat-to-down revenue in Q4. BeOne's Aaron Rosenberg said growth tracked consistently through the year and cited a roughly $50 million Q3 US BRUKINSA timing benefit from order timing and an extra shipping day.
• The 2027 margin outlook is modest. Rosenberg said on 5 November 2026 that 2027 operating expense growth should be at least consistent with recent years and that margin expansion should be "modest." He also said Medicare Part D changes will likely turn a modest 2026 tailwind into a flat-to-modest headwind in 2027.
• Management said XGEVA biosimilars and possible China volume-based purchasing for XGEVA and KYPROLIS will likely pressure revenue beyond 2026.
• BTK competition is contested. Goldman Sachs' Ziyi Chen asked about pirtobrutinib on the 5 November 2026 call. Management called BeOne the new-patient share leader but gave no share figure, and it criticised the control arm of the rival BRUIN CLL-313 trial.
• TEVIMBRA's own contribution is not isolated. Jazz's 23 October 2026 ESMO release gave a survival hazard ratio of 0.65 for zanidatamab plus TEVIMBRA and chemotherapy and 0.76 for zanidatamab plus chemotherapy, each against trastuzumab plus chemotherapy. It gave no head-to-head figure for the TEVIMBRA benefit.
• Rosenberg said on 5 November 2026 that he expects US net pricing to be "relatively stable" in 2027.

Price setup

The $387.25 close on 5 November 2026 is the 52-week high in adjusted daily closes. It sits above the $386.46 high in the previous note and the $373.36 close on 28 October 2026. The 14-day relative strength index was 59.5 on 5 November 2026, and the shares were up 7.9% over three months.

The September range low near $326 is the nearest major level beneath the shares. Crowding evidence is modest. The price sits at its high and every cited target is older than the report. BeOne's filing index listed a Form 144 proposed-sale notice dated 8 September 2026 and Form 4 reports dated 10 September 2026 and 16 September 2026.

Catalysts, next 30 days

• No company-dated event falls in the 30 days after 6 November 2026.
• Q4 2026 (no date published): BeOne plans a Japan submission for first-line mantle cell lymphoma and the start of the GroundBBreaker-301 and -201 liver-cancer trials.
• 14 December 2026: BeOne's ASH investor event, around the MANGROVE plenary presentation and 45 accepted abstracts. This falls outside the 30-day window, and the franchise case turns on it.
• Q4 2026 report (date not announced): This report shows actual 2026 revenue against the $6.9–7.0 billion range, the size of the expected tax benefit and the first detailed 2027 outlook.

What would change the view

The operating case breaks if 2026 revenue lands below the $6.9–7.0 billion range, or if US BRUKINSA growth falls well below Q2's 31% at the Q4 report. Either result would show that Q3 owed more to timing than to demand.

The franchise case weakens if MANGROVE's plenary results at ASH disappoint against the 43% reduction in progression or death announced on 30 June 2026. A published loss of new-patient share to pirtobrutinib would also damage it.

On price, a weekly close below $326 would put the shares under the September range low and undo the advance that followed the Q2 report.

What it trades with

BeOne's share moves are tied more to its own products than to one sector story. Three outside links matter. Eli Lilly's pirtobrutinib results and share data bear directly on BRUKINSA. Jazz's zanidatamab updates carry read-through to the TEVIMBRA regimen that the FDA approved in August 2026. US drug-pricing policy affects the whole large-cap biotech group, including BeOne.

The listings on Nasdaq, the Hong Kong exchange and the Shanghai STAR Market mean Asian trading often sets the US open.